MedTrace Logo

Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions

NCT00652886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2008-04-04

No results posted yet for this study

Summary

-To compare the single dose bioavailability of Kali and BTG

Conditions

  • To Determine the Bioequivalence Under Fasting Conditions

Interventions

DRUG

Oxandrolone

Tablets, 10mg, single-dose

DRUG

Oxandrin

tablets, 10mg, single-dose

Sponsors & Collaborators

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Herrmann · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-03-31
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652886 on ClinicalTrials.gov